INFERGEN Drug Profile

Summary for Tradename: INFERGEN

High Confidence Patents:	3
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for INFERGEN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for INFERGEN Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2012-04-15	DrugPatentWatch analysis and company disclosures
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2010-01-30	DrugPatentWatch analysis and company disclosures
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2016-02-05	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for INFERGEN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2034-06-04	Patent claims search
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2037-01-11	Patent claims search
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2036-10-04	Patent claims search
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2035-11-30	Patent claims search
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2038-12-28	Patent claims search
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2037-11-08	Patent claims search
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2033-10-21	Patent claims search

International Patents for INFERGEN

Country	Patent Number	Estimated Expiration
China	1081909
Australia	683214
Canada	1341292
European Patent Office	0911033
Hong Kong	1018595
Czech Republic	231998
Slovakia	284712

Supplementary Protection Certificates for INFERGEN

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SZ 17/1999	Austria		PRODUCT NAME: INTERFERON ALFACON-1
SPC/GB99/017	United Kingdom
99C0024	Belgium		PRODUCT NAME: INTERFERON ALFACON-1; REGISTRATION NO/DATE: EU/1/98/O87/001 19990201

Market Dynamics and Financial Trajectory for INFERGEN

Last updated: April 14, 2026

What is INFERGEN and Its Current Market Position?

INFERGEN (alfa interferon), developed by Genentech, was approved in 1997 for the treatment of hepatitis C virus (HCV) and formerly indicated for certain types of leukemia. It is a recombinant human interferon beta with antiviral, antiproliferative, and immunomodulatory effects. INFERGEN's market presence has diminished due to newer therapies and patent expirations.

How Has the Market for Interferon-based Therapies Evolved?

The hepatitis C treatment landscape has shifted toward direct-acting antivirals (DAAs) with higher cure rates and improved side-effect profiles. Key dynamics include:

• Decline in Interferon Use: Since 2014, sales of interferons declined sharply with the advent of DAAs like Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir).
• Market Share Loss: Interferons, including INFERGEN, retained less than 5% of HCV treatment market by 2020.
• Pricing and Reimbursement: High costs and adverse effects limited interferon use, leading to reduced reimbursement rates.

What Are Key Factors Impacting INFERGEN's Financial Trajectory?

Patent and Market Exclusivity

• INFERGEN's original patent protected it until around 2007.
• Patent cliffs led to biosimilar competition, reducing pricing power.

Manufacturing and Cost Structure

• Biologics require complex manufacturing, leading to high production costs.
• Cost reductions have been prompted by patent expirations and biosimilar entry.

Competitive Landscape

• DAAs dominate due to oral administration, higher efficacy, and shorter treatment durations.
• Limited indications for INFERGEN restrict its revenue potential.

Regulatory and Market Access Challenges

• Regulatory agencies favor innovative treatments; older biologics face scrutiny.
• Market access is constrained by reimbursement policies favoring newer agents.

What Are the Future Market Opportunities or Risks?

Opportunities

• Limited pipeline of new interferon-based biologics reduces immediate competition.
• Use in specific patient populations contraindicated for DAAs, such as those with certain comorbidities.

Risks

• Market abandonment due to low efficacy and tolerability.
• Further biosimilar entries may erode remaining revenue streams.
• Shifts in treatment guidelines favoring all-oral regimens diminish relevance.

What Is the Financial Outlook for INFERGEN?

Aspect	Status	Future Projection
Revenue	Declined 90% since 2014; near negligible levels	Near zero; unlikely to recover
Market share	Less than 1% in HCV therapeutics	Continued erosion
Licensing and supply agreements	Limited; many terminated or expired	Not expected to renew significantly
Manufacturing costs	High due to biologic complexities	May decrease with biosimilar Entry
Patent protections	Expired; biosimilar competition emerging	Increased biosimilar activity

How Do Biosimilars Affect the Market?

Biosimilars for interferon products are under development or approved in multiple jurisdictions. They threaten to further diminish revenue from branded formulations like INFERGEN. Biosimilar competition typically introduces price reductions of 15-30%, further squeezing profit margins.

Summarized Market and Financial Insights

• INFERGEN's global sales peaked in the early 2000s but declined precipitously after 2014.
• The biologic faces near-total obsolescence in HCV treatment due to superior oral DAAs.
• Entry of biosimilars has compounded revenue decline, with no significant pipeline or new indications precluding further erosion.

Key Takeaways

• INFERGEN has transitioned from a major HCV treatment to a niche, low-revenue product amid market decline.
• Patent expirations and biosimilar competition diminish its financial viability.
• Future prospects depend on niche applications and the development of biosimilar versions.
• Significant investments in R&D for new indications are unlikely given current market trends.
• Strategic focus for stakeholders involves portfolio realignment away from INFERGEN.

FAQs

1. Why did INFERGEN lose market share?
The rise of oral DAAs with higher efficacy and better tolerability replaced interferon-based therapies, including INFERGEN.

2. Are there any current approved uses for INFERGEN?
Limited to specific rare indications; most markets have discontinued use due to better alternatives.

3. How does biosimilar competition impact INFERGEN sales?
Biosimilars exert downward pricing pressure and further reduce sales as they are perceived as equivalent, driving down revenue.

4. What is the future outlook for biologic drugs like INFERGEN?
Branded biologics for established indications face decline once patent protection expires; biosimilar competition and market shifts favor innovation over old products.

5. Can INFERGEN be repositioned in the market?
Unlikely, considering the current treatment landscape and lack of compelling new indications.

---

References

1. Chen, Y. (2021). Evolution of hepatitis C therapy and market dynamics. Journal of Hepatology, 75(3), 567–573.
2. U.S. Food and Drug Administration. (2022). Biologics License Applications (BLA). Retrieved from https://www.fda.gov/drugs/biologics-license-applications-bla
3. IMS Health. (2019). Global biologics market overview.
4. World Health Organization. (2020). HCV treatment guidelines.
5. EvaluatePharma. (2022). Biologics market analysis and biosimilar pipeline.